Clinician Perspectives on Current Issues in Lung Cancer Drug Development

J Thorac Oncol. 2016 Sep;11(9):1387-96. doi: 10.1016/j.jtho.2016.05.009. Epub 2016 Jul 9.


Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.

Keywords: Clinical trials; Immunotherapy; Lung cancer; Targeted therapy.

Publication types

  • Review

MeSH terms

  • B7-H1 Antigen / analysis
  • B7-H1 Antigen / antagonists & inhibitors
  • Clinical Trials as Topic
  • Disease-Free Survival
  • Drug Discovery*
  • ErbB Receptors / genetics
  • Humans
  • Immunotherapy
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Molecular Targeted Therapy
  • Mutation
  • Research Design


  • B7-H1 Antigen
  • ErbB Receptors